Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report

Overview of attention for article published in Frontiers in oncology, February 2022

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age and source (58th percentile)

Mentioned by

twitter: 1 X user

Readers on

mendeley: 9 Mendeley

Summary X

So far, Altmetric has seen 2 X posts from 1 X users, with an upper bound of 2,454 followers.

Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring PRRC2B-ALK Rearrangement: A Case Report #lymphoma #lymsm https://t.co/23NXRijSqt

04 Mar 2022

Reply Repost Favourite

Durable Clinical Response to ALK Tyrosine Kinase Inhibitors in Epithelioid Inflammatory Myofibroblastic Sarcoma Harboring <em>PRRC2B-ALK</em> Rearrangement: A Case Report #lymphoma #lymsm https://t.co/MT9tGz4hny

03 Mar 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.